Data is not available for this company.
Data is not available for this company
Fulford was incorporated in 1948. It was then registered under the name C E Fulford and was 100% owned by C E Fulford Limited of UK. Until 1968, the company was engaged in the business of manufacturing and marketing pharmaceutical consumer products, including cough tablets and herbal ointments, marketed under the trademarks â€“ PEPS and ZAMBUK respectively.
The company offers medicines for the treatment of allergy & respiratory, arthritis & immunology, cancer therapies,
The company offers medicines for the treatment of allergy & respiratory, arthritis & immunology, cancer therapies, cardiovascular, hepatitis, sun care, etc.
Fulford is a subsidiary of Schering-Plough Corporation, USA, a leading research-based company, engaged primarily in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.
On July 1, 1968, Schering-Corporation, USA, an international research-based pharmaceutical company acquired 100% ownership of C. E. Fulford Limited, UK. Subsequently, a manufacturing plant was set up at Andheri for the manufacture of pharmaceutical products. The companyâ€™s operations commenced with the introduction of an antibiotic injection under the brand name GARAMYCIN and an antifungal skin solution under the brand name TINADERM.
In 1971, Schering Corporation merged with Plough Inc., a mass merchandiser of popular consumer products and Schering-Plough Corporation was formed. Schering-Plough has its headquarters and executive offices at New Jersey, USA.
In August 1981, the company changed its status from a private company to a public company and from January 1, 1982 diluted the foreign shareholding from 100% to 40%, to fall in line with the prevailing government policy. The shares of Fulford are listed on the Bombay Stock Exchange. There have been three bonus issues in the ratios of 1:1 since the public issue of shares.
It is committed to earning the trust of doctors, patients and customers every day. Their colleagues worldwide believe that trust is not easily granted, and that is the reason they focus each day on becoming a champion for their stakeholders. During the past few years, the company has been building a new kind of health care company. Their scientists are earning trust through the discovery and development of innovative, science-based medicines and services that improve the health and well-being of people around the world.
The test of being a true champion is to never give up and to passionately strive for even better outcomes. From their perspective as a health care company, that means helping people live better and live longer
Fulford offers medicines in the following areas:
Key Products of the company include:
Quadriderm RF, Dipsalic F, Elocon, Alaspan, Netromyicin, Remicade, Viraferon Peg, Integrilin etc.